Veverimer (TRC101)

About Renibus Therapeutics

Renibus Therapeutics is a private, clinical-stage biotech focused on cardiorenal and metabolic diseases with two late-stage assets. Its lead program, Veverimer, is entering a Phase 3 trial for CKD with metabolic acidosis and has received Orphan Drug Designation for anti-GBM disease. While its second Phase 3 asset, RBT-1, did not meet its primary endpoint in a cardiac surgery trial, the company is pursuing a refined development path in higher-risk patients based on post-hoc analysis. The company is led by industry veterans with a history of successful company build-outs and exits.

Therapeutic Areas